Outcomes
gastrointestinal symptoms, COVID-19-related severe/critical disease, ground-glass opacity, ageusia, anosmia
SECONDARY, INFILTRATION, ADVERSE EVENT
The primary endpoint was evaluated at day 14 - the median time to sustained clinical improvement or resolution of the nine above-mentioned major symptoms, rated as being less than or equal to mild (scored 1 or 0) and remained stable for >24 hours (see Supplementary File for the symptom diary cards).Pre-specified secondary endpoints included the proportion of patients with sustained improvement or resolution of nine major symptoms at day 14, the median time to sustained improvement or resolution of each of these individual symptoms, the median time to onset of antipyretic effect and return to normal temperature (axillary temperature ≤ 37.0°C or oral temperature ≤ 37.3°C for >24 hours), the median time to sustained improvement or resolution of gastrointestinal symptoms, anosmia and ageusia, the proportion of patients with sustained improvement or resolution of all symptoms, the time to negative conversion of NAAT findings, and the rate of NAAT negative conversion (days 0, 7, 10, 14), the proportion of patients with major improvement in chest imaging, the incidence of COVID-19-related severe/critical disease, COVID-19-related and all-cause mortality within day 14. A designated experienced radiologist (blinded to study allocation) reviewed chest X-ray or computed tomography (CT) images and rated the outcomes. An improvement in chest radiology denoted a decreased area of infiltration, a decreased area of any radiologic abnormality, or decreased density of ground-glass opacity or nodules [Safety endpoints were evaluated from the first dosing to the end of follow-up, including vital signs, physical examination, major changes in laboratory test, abnormal twelve-lead electrocardiogram findings, and the adverse event (AE) and serious adverse event (SAE). See 